Stockholm based Guard Therapeutics is trying to harness the natural properties of A1M (alpha-1-microglobulin) to protect the kidney
CEO Tobias Agervald explains how the lead program RMC-035 is being tested in conjunction with open heart surgery while smaller fragments of A1M are being developed for chronic kidney disease.